The Philadelphia Chromosome and CML - WEGO Health
Links shared publicly online about this topic.
- 1,180total visits
The Philadelphia Chromosome and CML - WEGO Health
View full resource at community.wegohealth.com
Tags: Cancer, Leukemia, Chronic Myelogenous Leukemia
Most Recently Shared on May 10, 2010 at 4:11 am By:
The Philadelphia Chromosome and CML http://bit.ly/9V5wle
Medical News:FDA Panel Backs Drug for Rare Type of Leukemia - in Oncology/Hematology, Leukemia from MedPage Today
medpagetoday.com — “Medical News:FDA Panel Backs Drug for Rare Type of Leukemia - in Oncology/Hematology, Leukemia from MedPage Today” View full resource at medpagetoday.com
Most Recently Shared on March 21, 2012 at 7:15 pm By:
Thomas Loarie, Jr Health Advocate
@medpagetoday FDA Panel Backs Drug for Rare Type of Leukemia http://t.co/gR2QLTID #medical #Health
NICE Final Recommendation Of Tasigna (nilotinib) For Some Ph+ Chronic Myeloid Leukaemia Patients Welcomed, UK - QualityPoint Technologies
qualitypointtech.net — “The decision by the National Institute for Health and Clinical Excellence (NICE) to recommend Tasigna (nilotinib) in the treatment of imatinib-resistant and imatinib-intolerant Philadelphia Chromosome (Ph+) chronic myeloid leukaemia (CML) was welcomed by Novartis Oncology. Although Dasatinib and high dose imatinib were appraised in the same setting, neither is recommended, with final Guidance expected to be in October 2011...” View full resource at qualitypointtech.net
Most Recently Shared on August 22, 2011 at 1:00 am By:
NICE Final Recommendation Of Tasigna (nilotinib) For Some Ph+ Chronic Myeloid Leukaemia Patients Welcomed, UK: The... http://t.co/GtzrvSG
EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review
news-medical.net — “Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in t” View full resource at news-medical.net
Most Recently Shared on August 18, 2011 at 6:08 am By:
Lung Cancer News: EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review: Pf... http://t.co/xnWLC0H
YouTube - The Philadelphia Chromosome.mov
youtube.com — “'D.O.C. The Media Medic' and Kareem Abdul Jabbar discuss Philadelphia Positive Chronic Myelogenous Leukemia on Hollywood Health News TV.” View full resource at youtube.com
Most Recently Shared on July 13, 2011 at 3:22 am By:
Long-Term Follow-Up of Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia After Stem Cell Mobilization Under Imatinib - OncologySTAT
oncologystat.com — “Leukemia and Lymphoma. 2010 Dec 6;[Epub Ahead of Print] - TD Kim, M Schwarz, KA Kreuzer, J Kaeda, K Movassaghi, P Grille, PT Daniel, B Dörken, P le Coutre” View full resource at oncologystat.com
Most Recently Shared on January 20, 2011 at 3:23 pm By:
OncologySTAT Oncology and Health Site
Story of the Week With Expert Commentary: 8-Year Follow-Up of Imatinib-Treated Ph+ CML in CCyR After AutoSCT http://tinyurl.com/5sg9ddc
European Union Approves Nilotinib First-Line Therapy for Ph+ CML - QualityPoint Technologies
qualitypointtech.net — “The European Commission has approved nilotinib for the first-line treatment of chronic-phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in adults. Medscape Medical News” View full resource at qualitypointtech.net
Most Recently Shared on January 4, 2011 at 4:46 am By:
European Union Approves Nilotinib First-Line Therapy for Ph+ CML: The European Commission has approved nilotinib f... http://bit.ly/ekA1fN
Phase 3 study of Tasigna for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) - ONA
oncologynurseadvisor.com — “Novartis announced new 24-month data from its Phase 3 trial comparing Tasigna (nilotinib) 150mg capsules to Gleevec (imatinib mesylate, from Novartis) tablets in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.” View full resource at oncologynurseadvisor.com
Most Recently Shared on December 7, 2010 at 9:45 pm By:
OncologyNurseAdvisor Nursing, Medical Education, Medical Publisher, and Oncology
Phase 3 study of Tasigna for the treatment of Philadelphia chromosome-positive chronic… http://goo.gl/fb/rC5hQ
Therapeutic Potential of Bosutinib Observed in Patients With Chronic-Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy With Dasatinib or Nilotinib - ONA
oncologynurseadvisor.com — “Bosutinib has therapeutic potential in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic-phase (CP) chronic myeloid leukemia (CML) with resistance to--"or, particularly, intolerance to--"other second-generation tyrosine kinase inhibitor (TKI) therapies, results of an open-label, phase 1/2 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition has found.” View full resource at oncologynurseadvisor.com
Most Recently Shared on December 7, 2010 at 6:02 pm By:
OncologyNurseAdvisor Nursing, Medical Education, Medical Publisher, and Oncology
Therapeutic Potential of Bosutinib Observed in Patients With Chronic-Phase Chronic Myeloid… http://goo.gl/fb/rME5H
Novartis: Tasigna surpasses Glivec in study - FiercePharma
fiercepharma.com — “Tasigna continues to surpass Glivec as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, according to a statement issued... Read more...” View full resource at fiercepharma.com
Most Recently Shared on December 6, 2010 at 1:21 pm By:
Novartis: Tasigna surpasses Glivec in study. http://bit.ly/ejB1GY
Longer-term Phase III Data Show Novartis Drug Tasigna Continues to Surpass Gleevec in Slowing Disease Progression in Patients with Newly Diagnosed CML - Drugs.com MedNews
drugs.com — “EAST HANOVER, N.J., Fewer patients taking Tasigna for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase progressed to advanced stages o” View full resource at drugs.com
Most Recently Shared on December 6, 2010 at 1:01 pm By:
Drugs and Devices OW OW Health
Longer-term Phase III Data Show Novartis Drug Tasigna Continues to Surpass Gleevec in Slowing Disease Prog... http://bit.ly/dG4s34 #drug
SPRYCEL receives FDA approval for adult patients with Ph+ CML in chronic phase
news-medical.net — “After receiving a priority review, Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved SPRYCEL (dasatinib) 100 mg once daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.” View full resource at news-medical.net
Most Recently Shared on October 29, 2010 at 7:58 am By:
SPRYCEL receives FDA approval for adult patients with Ph+ CML in chronic phase: After receiving a priority review,... http://bit.ly/cVEfdN
FDA approves additional medical indication for Sprycel
drugs.com — “Sprycel (dasatinib) is now approved to treat newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. Includes Sprycel side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on October 28, 2010 at 11:24 pm By:
Drugs and Devices OW OW Health
FDA approves additional medical indication for Sprycel: SILVER SPRING, Md., Oct. 28 - The U.S. Food and Drug ... http://bit.ly/cA1b5e #drug
FDA approves additional medical indication for Sprycel
drugs.com — “Sprycel (dasatinib) is now approved to treat newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. Includes Sprycel side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on October 28, 2010 at 10:35 pm By:
FDA approves additional medical indication for Sprycel - http://bit.ly/cudetK
Medical News: Dasatinib Wins First-Line Indication in CML - in Oncology/Hematology, Leukemia from MedPage Today
medpagetoday.com — “WASHINGTON -- The FDA approved an additional indication for dasatinib (Sprycel) as a first-line therapy for patients with Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ C” View full resource at medpagetoday.com
Most Recently Shared on October 28, 2010 at 9:29 pm By:
Dasatinib Wins First-Line Indication in CML http://ow.ly/19GFT4
Sprycel gains indication for Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML) - MPR
empr.com — “Bristol-Myers Squibb announced that the FDA granted accelerated approval to Sprycel (dasatinib) for the first-line treatment of Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML).” View full resource at empr.com
Most Recently Shared on October 28, 2010 at 8:16 pm By:
MPR News: Sprycel gains indication for Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph... http://bit.ly/dlK474
Advertisement
